<DOC>
	<DOCNO>NCT01483911</DOCNO>
	<brief_summary>ALX-0171 Nanobody direct human respiratory syncytial virus ( RSV ) . The purpose first-in-man study determine safety , tolerability pharmacokinetics ( PK ) ALX-0171 single multiple pulmonary administration healthy male volunteer .</brief_summary>
	<brief_title>ALX-0171 Phase I Study , Evaluating Single Ascending Dose Multiple Dose Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Nonsmoking healthy male volunteer , age 1855 year Good health condition , determine medical history , physical examination clinical laboratory test Forced expiratory volume 1 second ( FEV1 ) ≥ 90 % predict value Diffusing capacity lung CO ( DLCO ) ≥ 85 % predict value Normal chest XRay ( anteroposterior lateral view ) Minimum weight 70.0 kg , minimum height 1m70 , body mass index 18.0 30.0 kg/m² Current smoker , exsmokers abstinent tobacco le one year History presence atopy pulmonary nonspecific hyperreactivity Positive bronchial challenge test Symptomatic viral infection , suspicion thereof ( include rhinitis ) last 14 day prior dose Signs active pulmonary infection inflammatory condition , even absence febrile episode , last 14 day prior dose</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>